Boston Scientific Corp. vs. Daxor Corporation Common Stock
Boston Scientific Corp. and Daxor Corporation Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BSX | DXR | |
|---|---|---|
| Market Cap | $60.84 billion | $66.85 million |
| Revenue (TTM) | — | $1.45 million |
| Net Income (TTM) | — | $-7,185,639 |
BSX leads on 1 of 1 size & scale factors.
Valuation
| BSX | DXR | |
|---|---|---|
| Price / Book | — | 1.85 |
| Price / Sales | — | 46.22 |
BSX and DXR split the valuation factors evenly.
Profitability
| BSX | DXR | |
|---|---|---|
| Net Margin | — | -496.81% |
| Return on Equity | — | -19.84% |
BSX and DXR split the profitability factors evenly.
Dividend
| BSX | DXR | |
|---|---|---|
| Dividend Yield | — | 0.26% |
BSX and DXR split the dividend factors evenly.
Risk & Sentiment
| BSX | DXR | |
|---|---|---|
| Short Interest | 0.72% | 0.00% |
DXR leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, DXR overview, DXR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.